- Home
- PRTA vs GOSS Comparison
PRTA vs GOSS Comparison
Compare PRTA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- GOSS
- Stock Information
- Founded
- PRTA 2012
- GOSS 2015
- Country
- PRTA Ireland
- GOSS United States
- Employees
- PRTA N/A
- GOSS N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- PRTA Health Care
- GOSS Health Care
- Exchange
- PRTA Nasdaq
- GOSS Nasdaq
- Market Cap
- PRTA 472.1M
- GOSS 347.8M
- IPO Year
- PRTA N/A
- GOSS 2019
- Fundamental
- Price
- PRTA $8.20
- GOSS $2.47
- Analyst Decision
- PRTA Buy
- GOSS Strong Buy
- Analyst Count
- PRTA 10
- GOSS 4
- Target Price
- PRTA $14.86
- GOSS $8.50
- AVG Volume (30 Days)
- PRTA 1.2M
- GOSS 3.1M
- Earning Date
- PRTA 08-04-2025
- GOSS 08-05-2025
- Dividend Yield
- PRTA N/A
- GOSS N/A
- EPS Growth
- PRTA N/A
- GOSS N/A
- EPS
- PRTA N/A
- GOSS N/A
- Revenue
- PRTA $10,341,000.00
- GOSS $40,237,000.00
- Revenue This Year
- PRTA N/A
- GOSS N/A
- Revenue Next Year
- PRTA $389.77
- GOSS $30.65
- P/E Ratio
- PRTA N/A
- GOSS N/A
- Revenue Growth
- PRTA N/A
- GOSS N/A
- 52 Week Low
- PRTA $4.32
- GOSS $0.66
- 52 Week High
- PRTA $22.83
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- PRTA 58.73
- GOSS 68.08
- Support Level
- PRTA $8.05
- GOSS $2.38
- Resistance Level
- PRTA $8.73
- GOSS $2.65
- Average True Range (ATR)
- PRTA 0.38
- GOSS 0.15
- MACD
- PRTA -0.05
- GOSS 0.03
- Stochastic Oscillator
- PRTA 47.62
- GOSS 76.67
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.